Foresight Capital's model of investing across early, middle, and late stages from one fund provides a unique advantage. Their understanding of late-stage market needs and challenges directly informs and improves their selection process for early-stage companies, creating a powerful feedback loop that specialized VCs lack.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.

Observing hype around CAR-T for autoimmune diseases, Foresite recognized its commercial impracticality for non-oncology patients. They hypothesized that off-the-shelf T-cell engagers could achieve similar results with better convenience, leading them to incubate Candid Therapeutics, which UCB acquired for $2B.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

While staying private can offer strategic advantages, particularly for future M&A, the biotech industry lacks a mature private growth capital market. Companies needing hundreds of millions for late-stage trials have no choice but to go public, unlike their tech counterparts.

David Craver asserts that being an active private market investor is an "imperative" for success in public markets. The research and insights gained from late-stage, pre-IPO companies provide crucial information that directly informs and strengthens a firm's public equity investment strategy in an interconnected landscape.

OMX Ventures invests across tools, diagnostics, and therapeutics because "tools lead to new insights that lead to new products." This strategy provides a "front row seat" to emerging technologies, allowing them to understand a new tool's power and application before the broader market. This information arbitrage leads to smarter investments across their entire portfolio.